Literature DB >> 8460089

Diagnostic significance of cancer-associated carbohydrate antigen (CA19-9) concentrations in pancreatic juice: analysis in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis.

T Wakabayashi1, N Sawabu, Y Takemori, Y Satomura, H Kidani, H Ohta, H Watanabe, O Yamakawa, H Takahashi, K Watanabe.   

Abstract

This study evaluated the diagnostic significance of concentrations of the cancer-associated carbohydrate antigen CA19-9 in pure pancreatic juice (PPJ) collected by endoscopic cannulation. We also attempted to elucidate the features and source of the increased CA19-9 concentration found in the pancreatic juice of patients with chronic pancreatitis (CP) by means of immunohistochemical staining. The mean output as well as the mean concentration of CA19-9 in each of the four fractions collected was highest in patients with pancreatic cancer (PC) and also was elevated significantly in patients with CP compared with controls. However, CA19-9 concentrations were not elevated in patients with cholecystolithiasis. When the cutoff value was set as the mean concentration + 2SD of the controls, significantly elevated concentrations of CA19-9 were found in the third fraction (secretory phase) in 90% of the patients with PC and 66% of the patients with CP. Immunohistochemical staining revealed that CA19-9 was expressed more widely in the ductal cells of CP tissues than in those of normal pancreatic (NP) tissues, with CP tissue showing more CA19-9-positive ductal cells per area than NP tissues. In NP tissue, CA19-9 was localized to the apical surface and supranuclear regions (apical type) in all the ductal cells stained by the antigen, while approximately 50% of cases with CP exhibited a cytoplasmic pattern showing a loss of polarity of the antigen expression. Moreover, this cellular localization pattern was more pronounced in the small ducts that had proliferated and aggregated following the destruction of lobules in CP.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460089     DOI: 10.1097/00006676-199303000-00003

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas.

Authors:  Sukhwinder Kaur; Michael J Baine; Sushovan Guha; Nobuo Ochi; Subhankar Chakraborty; Kavita Mallya; Colleen Thomas; Julia Crook; Michael B Wallace; Timothy A Woodward; Maneesh Jain; Shailender Singh; Aaron R Sasson; Verna Skinner; Massimo Raimondo; Surinder K Batra
Journal:  Pancreas       Date:  2013-04       Impact factor: 3.327

2.  Pancreatic cyst as a sentinel of in situ carcinoma of the pancreas. Report of two cases.

Authors:  K Yamaguchi; K Nakamura; K Yokohata; S Shimizu; K Chijiiwa; M Tanaka
Journal:  Int J Pancreatol       Date:  1997-12

3.  Measurement of sialylated stage-specific embryonic antigen-1 in pure pancreatic juice for the diagnosis of pancreatic cancer.

Authors:  H Ohta; N Sawabu; Y Takemori; H Kidani; T Wakabayashi; Y Satomura; H Watanabe; Y Motoo; T Okai; H Takahashi
Journal:  Int J Pancreatol       Date:  1994-02

4.  Detection of K-ras point mutations at codon 12 in pancreatic juice for the diagnosis of pancreatic cancer by hybridization protection assay: a simple method for the determination of the types of point mutation.

Authors:  H Watanabe; C Miyagi; Y Yamaguchi; Y Satomura; H Ohta; Y Motoo; T Okai; T Yoshimura; Y Tsuji; N Sawabu
Journal:  Jpn J Cancer Res       Date:  1996-05

5.  Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers.

Authors:  H Watanabe; N Sawabu; H Ohta; Y Satomura; O Yamakawa; Y Motoo; T Okai; H Takahashi; T Wakabayashi
Journal:  Jpn J Cancer Res       Date:  1993-09

Review 6.  Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics.

Authors:  Célia Cintas; Thibaut Douché; Nicole Therville; Silvia Arcucci; Fernanda Ramos-Delgado; Céline Basset; Benoît Thibault; Julie Guillermet-Guibert
Journal:  Cancers (Basel)       Date:  2018-06-01       Impact factor: 6.639

Review 7.  Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

Authors:  Robert S O'Neill; Alina Stoita
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.